BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12412819)

  • 1. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
    Madani S; Barilla D; Cramer J; Wang Y; Paul C
    J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
    Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
    J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.
    Harris RZ; Salfi M; Posvar E; Hoelscher D; Padhi D
    Eur J Clin Pharmacol; 2007 Feb; 63(2):159-63. PubMed ID: 16680561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
    Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
    Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
    Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
    Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
    Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
    Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
    Nguyen HQ; Callegari E; Obach RS
    Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
    Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
    Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
    Spina E; Gitto C; Avenoso A; Campo GM; Caputi AP; Perucca E
    Eur J Clin Pharmacol; 1997; 51(5):395-8. PubMed ID: 9049581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
    Bergmann TK; Bathum L; Brosen K
    Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
    Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
    Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
    J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.